Author(s): Tang Y, Zhu W, Chen K, Jiang H
Abstract Share this page
Abstract In the postgenomic era, computer-aided drug design (CADD) has considerably extended its range of applications, spanning almost all stages in the drug discovery pipeline, from target identification to lead discovery, from lead optimization to preclinical or clinical trials. Two new technologies of CADD associated with target identification and new chemical entity discovery will be the focus of this review.: © 2006 Elsevier Ltd . All rights reserved.
This article was published in Drug Discov Today Technol
and referenced in Drug Designing: Open Access